View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsGlobal Bioenergies 배당 및 자사주 매입배당 기준 점검 0/6Global Bioenergies 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-17.9%자사주 매입 수익률총 주주 수익률-17.9%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Sep 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.0m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Revenue is less than US$1m (€361k revenue, or US$424k). Market cap is less than US$10m (€600.0k market cap, or US$704.9k). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Jun 05Consensus EPS estimates fall by 54%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.505 to -€0.78 per share. Revenue forecast of €600.0k unchanged since last update. Chemicals industry in France expected to see average net income growth of 9.8% next year. Consensus price target of €2.40 unchanged from last update. Share price fell 93% to €0.062 over the past week.New Risk • Jun 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €1.54m (US$1.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.0m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Revenue is less than US$1m (€361k revenue, or US$412k). Market cap is less than US$10m (€1.54m market cap, or US$1.76m). Minor Risk Currently unprofitable and not forecast to become profitable next year (€8.4m net loss next year).분석 기사 • May 21Is Global Bioenergies (EPA:ALGBE) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...공시 • Mar 22Global Bioenergies SA, Annual General Meeting, May 15, 2025Global Bioenergies SA, Annual General Meeting, May 15, 2025. Location: 5 rue henri desbrueres, evry courcouronnes FranceMajor Estimate Revision • Mar 21Consensus EPS estimates fall by 53%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.511 to -€0.782 per share. Revenue forecast of €570.0k unchanged since last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target of €2.40 unchanged from last update. Share price fell 2.6% to €1.26 over the past week.Major Estimate Revision • Feb 10Consensus revenue estimates fall by 72%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €2.07m to €570.0k. Forecast losses increased from -€0.501 to -€0.511 per share. Chemicals industry in France expected to see average net income growth of 22% next year. Consensus price target of €2.40 unchanged from last update. Share price rose 6.3% to €1.21 over the past week.New Risk • Feb 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.7m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.7m). Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.2m net loss in 2 years). Revenue is less than US$5m (€4.7m revenue, or US$4.9m). Market cap is less than US$100m (€21.8m market cap, or US$22.5m).Reported Earnings • Feb 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €4.69m (up 44% from FY 2023). Net loss: €5.86m (loss narrowed 32% from FY 2023). Revenue is expected to decline by 124% p.a. on average during the next 2 years, while revenues in the Chemicals industry in France are expected to grow by 5.1%.New Risk • Oct 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$580k). Market cap is less than US$10m (€8.84m market cap, or US$9.57m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).New Risk • Oct 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€146k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$585k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (€24.0m market cap, or US$26.2m).Buy Or Sell Opportunity • Oct 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to €1.32. The fair value is estimated to be €1.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 447% in 2 years. Earnings are forecast to decline by 15% in the next 2 years.분석 기사 • Sep 18Global Bioenergies SA's (EPA:ALGBE) Intrinsic Value Is Potentially 60% Above Its Share PriceKey Insights Global Bioenergies' estimated fair value is €2.44 based on 2 Stage Free Cash Flow to Equity Global...Major Estimate Revision • Sep 11Consensus revenue estimates decrease by 51%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €1.75m to €860.0k. EPS estimate increased from -€0.545 to -€0.524 per share. Chemicals industry in France expected to see average net income growth of 23% next year. Consensus price target of €2.60 unchanged from last update. Share price fell 3.7% to €1.61 over the past week.분석 기사 • Jun 21Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • May 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€33.2m market cap, or US$36.1m).공시 • May 12Global Bioenergies SA, Annual General Meeting, Jun 27, 2024Global Bioenergies SA, Annual General Meeting, Jun 27, 2024. Location: 5 rue henri desbrueres, evry courcouronnes FranceNew Risk • Apr 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 6.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Market cap is less than US$100m (€36.9m market cap, or US$39.3m).Major Estimate Revision • Apr 11Consensus revenue estimates fall by 45%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from €3.20m to €1.75m. Forecast losses increased from -€0.14 to -€0.455 per share. Chemicals industry in France expected to see average net income growth of 20% next year. Consensus price target down from €4.00 to €2.40. Share price rose 4.0% to €2.02 over the past week.Reported Earnings • Mar 07Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in France are expected to grow by 5.0%.공시 • Oct 19Global Bioenergies Announces the Appointment of Martin Stephan as Chief Business OfficerGlobal Bioenergies announced Martin Stephan joins the company as chief business officer. Martin Stephan has spent his entire career in the chemical industry, in France, Germany, Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022, he notably contributed to the strong growth of this major listed player in the green chemistry market. He previously held strategic positions as Head of International Sales in global groups, particularly in The Chemours Company and Du Pont de Nemours, the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.Reported Earnings • Sep 21First half 2023 earnings releasedFirst half 2023 results: Revenue: €7.33m (up €7.22m from 1H 2022). Net loss: €4.08m (loss narrowed 29% from 1H 2022). Revenue is expected to decline by 29% p.a. on average during the next 3 years, while revenues in the Chemicals industry in France are expected to grow by 4.4%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.분석 기사 • Jun 28Is Global Bioenergies (EPA:ALGBE) Using Debt Sensibly?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Major Estimate Revision • May 17Consensus EPS estimates fall by 26%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.48 to -€0.605 per share. Revenue forecast of €6.40m unchanged since last update. Chemicals industry in France expected to see average net income growth of 16% next year. Consensus price target down from €5.60 to €5.15. Share price rose 15% to €2.38 over the past week.Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.Price Target Changed • Mar 30Price target decreased by 22% to €5.60Down from €7.15, the current price target is an average from 2 analysts. New target price is 164% above last closing price of €2.12. Stock is down 58% over the past year.Major Estimate Revision • Feb 21Consensus EPS estimates upgraded to €0.22 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -€0.475 to -€0.22 per share. Revenue forecast unchanged from €10.7m at last update. Chemicals industry in France expected to see average net income growth of 24% next year. Consensus price target of €7.05 unchanged from last update. Share price was steady at €2.85 over the past week.Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in France.Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.Price Target Changed • Dec 13Price target increased to €16.37Up from €7.15, the current price target is an average from 3 analysts. New target price is 353% above last closing price of €3.62. Stock is down 21% over the past year. The company is forecast to post a net loss per share of €0.75 next year compared to a net loss per share of €0.79 last year.분석 기사 • Oct 11Global Bioenergies (EPA:ALGBE) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Price Target Changed • Sep 27Price target decreased to €7.15Down from €7.75, the current price target is provided by 1 analyst. New target price is 99% above last closing price of €3.59. Stock is down 40% over the past year. The company is forecast to post a net loss per share of €0.71 next year compared to a net loss per share of €0.79 last year.Reported Earnings • Mar 06Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.88m (up €3.82m from FY 2020). Net loss: €11.8m (loss widened 5.6% from FY 2020). Revenue exceeded analyst estimates by 3,781%. Over the next year, revenue is expected to shrink by 33% compared to a 12% growth forecast for the industry in France.Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.분석 기사 • Oct 25Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Breakeven Date Change • May 18No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.Reported Earnings • Apr 25Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.분석 기사 • Mar 20Global Bioenergies (EPA:ALGBE) Shareholders Have Enjoyed An Impressive 187% Share Price GainGlobal Bioenergies SA ( EPA:ALGBE ) shareholders might be concerned after seeing the share price drop 11% in the last...Reported Earnings • Mar 19Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).Is New 90 Day High Low • Jan 15New 90-day high: €9.48The company is up 201% from its price of €3.15 on 16 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.Is New 90 Day High Low • Nov 24New 90-day high: €4.14The company is up 17% from its price of €3.54 on 26 August 2020. The French market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ALGBE 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ALGBE 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Global Bioenergies 배당 수익률 vs 시장ALGBE의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ALGBE)n/a시장 하위 25% (FR)2.0%시장 상위 25% (FR)5.6%업계 평균 (Chemicals)2.2%분석가 예측 (ALGBE) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ALGBE 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ALGBE 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ALGBE 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ALGBE 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YFR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/04 04:40종가2025/12/04 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Global Bioenergies SA는 6명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Markus MayerBaader Helvea Equity ResearchMark CartlichEdison Investment ResearchAlexandre LetzGilbert Dupont3명의 분석가 더 보기
New Risk • Sep 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.0m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Revenue is less than US$1m (€361k revenue, or US$424k). Market cap is less than US$10m (€600.0k market cap, or US$704.9k). Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Marie-Odile Lavenant was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Jun 05Consensus EPS estimates fall by 54%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.505 to -€0.78 per share. Revenue forecast of €600.0k unchanged since last update. Chemicals industry in France expected to see average net income growth of 9.8% next year. Consensus price target of €2.40 unchanged from last update. Share price fell 93% to €0.062 over the past week.
New Risk • Jun 05New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €1.54m (US$1.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.0m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Revenue is less than US$1m (€361k revenue, or US$412k). Market cap is less than US$10m (€1.54m market cap, or US$1.76m). Minor Risk Currently unprofitable and not forecast to become profitable next year (€8.4m net loss next year).
분석 기사 • May 21Is Global Bioenergies (EPA:ALGBE) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
공시 • Mar 22Global Bioenergies SA, Annual General Meeting, May 15, 2025Global Bioenergies SA, Annual General Meeting, May 15, 2025. Location: 5 rue henri desbrueres, evry courcouronnes France
Major Estimate Revision • Mar 21Consensus EPS estimates fall by 53%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€0.511 to -€0.782 per share. Revenue forecast of €570.0k unchanged since last update. Chemicals industry in France expected to see average net income growth of 18% next year. Consensus price target of €2.40 unchanged from last update. Share price fell 2.6% to €1.26 over the past week.
Major Estimate Revision • Feb 10Consensus revenue estimates fall by 72%The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €2.07m to €570.0k. Forecast losses increased from -€0.501 to -€0.511 per share. Chemicals industry in France expected to see average net income growth of 22% next year. Consensus price target of €2.40 unchanged from last update. Share price rose 6.3% to €1.21 over the past week.
New Risk • Feb 06New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.7m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€5.7m). Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.2m net loss in 2 years). Revenue is less than US$5m (€4.7m revenue, or US$4.9m). Market cap is less than US$100m (€21.8m market cap, or US$22.5m).
Reported Earnings • Feb 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €4.69m (up 44% from FY 2023). Net loss: €5.86m (loss narrowed 32% from FY 2023). Revenue is expected to decline by 124% p.a. on average during the next 2 years, while revenues in the Chemicals industry in France are expected to grow by 5.1%.
New Risk • Oct 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.84m (US$9.57m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$580k). Market cap is less than US$10m (€8.84m market cap, or US$9.57m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding).
New Risk • Oct 10New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€146k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€146k). Earnings are forecast to decline by an average of 4.0% per year for the foreseeable future. Revenue is less than US$1m (€535k revenue, or US$585k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€8.5m net loss in 2 years). Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (€24.0m market cap, or US$26.2m).
Buy Or Sell Opportunity • Oct 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 27% to €1.32. The fair value is estimated to be €1.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 447% in 2 years. Earnings are forecast to decline by 15% in the next 2 years.
분석 기사 • Sep 18Global Bioenergies SA's (EPA:ALGBE) Intrinsic Value Is Potentially 60% Above Its Share PriceKey Insights Global Bioenergies' estimated fair value is €2.44 based on 2 Stage Free Cash Flow to Equity Global...
Major Estimate Revision • Sep 11Consensus revenue estimates decrease by 51%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €1.75m to €860.0k. EPS estimate increased from -€0.545 to -€0.524 per share. Chemicals industry in France expected to see average net income growth of 23% next year. Consensus price target of €2.60 unchanged from last update. Share price fell 3.7% to €1.61 over the past week.
분석 기사 • Jun 21Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • May 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.7% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (€33.2m market cap, or US$36.1m).
공시 • May 12Global Bioenergies SA, Annual General Meeting, Jun 27, 2024Global Bioenergies SA, Annual General Meeting, Jun 27, 2024. Location: 5 rue henri desbrueres, evry courcouronnes France
New Risk • Apr 12New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 6.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 6.0% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€9.5m net loss in 2 years). Market cap is less than US$100m (€36.9m market cap, or US$39.3m).
Major Estimate Revision • Apr 11Consensus revenue estimates fall by 45%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from €3.20m to €1.75m. Forecast losses increased from -€0.14 to -€0.455 per share. Chemicals industry in France expected to see average net income growth of 20% next year. Consensus price target down from €4.00 to €2.40. Share price rose 4.0% to €2.02 over the past week.
Reported Earnings • Mar 07Full year 2023 earnings releasedFull year 2023 results: Revenue: €8.91m (up €8.33m from FY 2022). Net loss: €8.66m (loss narrowed 28% from FY 2022). Revenue is expected to decline by 53% p.a. on average during the next 2 years, while revenues in the Chemicals industry in France are expected to grow by 5.0%.
공시 • Oct 19Global Bioenergies Announces the Appointment of Martin Stephan as Chief Business OfficerGlobal Bioenergies announced Martin Stephan joins the company as chief business officer. Martin Stephan has spent his entire career in the chemical industry, in France, Germany, Italy and Switzerland. As Deputy Chief Executive Officer of CARBIOS from 2017 to 2022, he notably contributed to the strong growth of this major listed player in the green chemistry market. He previously held strategic positions as Head of International Sales in global groups, particularly in The Chemours Company and Du Pont de Nemours, the world leader in innovative specialty products for industry. Martin Stephan is a graduate of HEC.
Reported Earnings • Sep 21First half 2023 earnings releasedFirst half 2023 results: Revenue: €7.33m (up €7.22m from 1H 2022). Net loss: €4.08m (loss narrowed 29% from 1H 2022). Revenue is expected to decline by 29% p.a. on average during the next 3 years, while revenues in the Chemicals industry in France are expected to grow by 4.4%. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
분석 기사 • Jun 28Is Global Bioenergies (EPA:ALGBE) Using Debt Sensibly?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Major Estimate Revision • May 17Consensus EPS estimates fall by 26%The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -€0.48 to -€0.605 per share. Revenue forecast of €6.40m unchanged since last update. Chemicals industry in France expected to see average net income growth of 16% next year. Consensus price target down from €5.60 to €5.15. Share price rose 15% to €2.38 over the past week.
Board Change • Apr 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Chairman Corinne Granger was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Breakeven Date Change • Mar 31No longer forecast to breakevenThe analyst covering Global Bioenergies no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €4.70m in 2025. New forecast suggests the company will make a loss of €1.30m in 2025.
Price Target Changed • Mar 30Price target decreased by 22% to €5.60Down from €7.15, the current price target is an average from 2 analysts. New target price is 164% above last closing price of €2.12. Stock is down 58% over the past year.
Major Estimate Revision • Feb 21Consensus EPS estimates upgraded to €0.22 lossThe consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -€0.475 to -€0.22 per share. Revenue forecast unchanged from €10.7m at last update. Chemicals industry in France expected to see average net income growth of 24% next year. Consensus price target of €7.05 unchanged from last update. Share price was steady at €2.85 over the past week.
Breakeven Date Change • Feb 21Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests losses will reduce by 31% per year to 2024. The company is expected to make a profit of €4.70m in 2025. Average annual earnings growth of 67% is required to achieve expected profit on schedule.
Reported Earnings • Feb 17Full year 2022 earnings releasedFull year 2022 results: Revenue: €1.72m (up 106% from FY 2021). Net loss: €12.0m (loss widened 1.8% from FY 2021). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Chemicals industry in France.
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The analyst covering Global Bioenergies expects the company to break even for the first time. New forecast suggests the company will make a profit of €4.70m in 2025. Average annual earnings growth of 39% is required to achieve expected profit on schedule.
Price Target Changed • Dec 13Price target increased to €16.37Up from €7.15, the current price target is an average from 3 analysts. New target price is 353% above last closing price of €3.62. Stock is down 21% over the past year. The company is forecast to post a net loss per share of €0.75 next year compared to a net loss per share of €0.79 last year.
분석 기사 • Oct 11Global Bioenergies (EPA:ALGBE) Has Debt But No Earnings; Should You Worry?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Price Target Changed • Sep 27Price target decreased to €7.15Down from €7.75, the current price target is provided by 1 analyst. New target price is 99% above last closing price of €3.59. Stock is down 40% over the past year. The company is forecast to post a net loss per share of €0.71 next year compared to a net loss per share of €0.79 last year.
Reported Earnings • Mar 06Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.88m (up €3.82m from FY 2020). Net loss: €11.8m (loss widened 5.6% from FY 2020). Revenue exceeded analyst estimates by 3,781%. Over the next year, revenue is expected to shrink by 33% compared to a 12% growth forecast for the industry in France.
Breakeven Date Change • Feb 01Forecast to breakeven in 2024The 2 analysts covering Global Bioenergies expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €700.0k in 2024. Average annual earnings growth of 48% is required to achieve expected profit on schedule.
분석 기사 • Oct 25Does Global Bioenergies (EPA:ALGBE) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Oct 03First half 2021 earnings released: €0.69 loss per share (vs €0.80 loss in 1H 2020)First half 2021 results: Net loss: €7.62m (loss widened 9.9% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Breakeven Date Change • May 18No longer forecast to breakevenThe 2 analysts covering Global Bioenergies no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €4.20m in 2023. New consensus forecast suggests the company will make a loss of €7.65m in 2023.
Reported Earnings • Apr 25Full year 2020 earnings released: €1.10 loss per share (vs €1.65 loss in FY 2019)Full year 2020 results: Net loss: €11.1m (loss narrowed 23% from FY 2019). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 20Global Bioenergies (EPA:ALGBE) Shareholders Have Enjoyed An Impressive 187% Share Price GainGlobal Bioenergies SA ( EPA:ALGBE ) shareholders might be concerned after seeing the share price drop 11% in the last...
Reported Earnings • Mar 19Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.28m (up €3.16m from FY 2019). Net loss: €11.1m (loss narrowed 13% from FY 2019).
Is New 90 Day High Low • Jan 15New 90-day high: €9.48The company is up 201% from its price of €3.15 on 16 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.
Is New 90 Day High Low • Nov 24New 90-day high: €4.14The company is up 17% from its price of €3.54 on 26 August 2020. The French market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 2.0% over the same period.
Reported Earnings • Sep 21First half earnings releasedOver the last 12 months the company has reported total losses of €12.1m, with losses narrowing by 2.5% from the prior year.